Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that the U.S. Food and ...
Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
SAN FRANCISCO -- Janus kinase (JAK) inhibitors appeared to be a safe, effective option for treating inflammatory bowel ...
Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.In an interview with Healio, ...
“We found that pharmacologically targeting a single kinase, CDK2, can trigger two distinct cellular responses depending on the tumor type,” said Vishnu Kumarasamy, PhD, first author on the new study ...
In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback